Critically-ill newborn babies will benefit
from the administration of nitric oxide inhalation therapy, thanks to
world-leading NO gas sensors from City Technology Limited in the UK.
 |
Specially-developed for the medical market, these sensors have been crucial in bringing this therapy to neonatal medicine, which stands to benefit thousands of babies worldwide. NO therapy has become one of the most exciting research areas in ventilator therapy since the discovery of NO as an extremely effective pulmonary vasodilator. NO inhalation therapy reduces the 'blue babies'' need for invasive surgery and is being greeted as one of the most important breakthroughs in this area for many years. |
The USA Food & Drug Administration has approved this therapy for use
in the treatment of neonates with 'blue baby syndrome', or hypoxic respiratory
failure, after several years of clinical trials. City Technology sensors
used in the early trials period have enabled City to develop a superior
design, dedicated medical product. These sensors are now being used in
equipment manufactured by Siemens, Messer Griesheim and many others including
AGA Europe.
These new sensors, the MN0-1 and the compact MNO-2, offer superior performance
with no cross-interference from agent gases or N2O. They boast fast T90
response times of less than 10 seconds and temperature compensation. They
are both totally unaffected by operation in 100% O2.
Within neonatal critical care areas, sensor reliability is crucial for
patient well being, care delivery and keeping downtime of care facilities
to a minimum. City operates stringent quality control and rigorous testing
procedures within their production facility in Portsmouth, UK and has
recently received ISO9001 and EN46001 quality accreditation. The production
processes for the MNO sensors are performed by a dedicated team, and incorporate
automatic checks such that each stage cannot be carried out unless the
previous stage was 100% correct.
David Baines, Director - Medical Applications: 'This approval from the
FDA is really great news for us and will be of huge benefit to neonatal
clinicians. These new sensors are just one example of City's ability and
willingness to co-develop customised products, and we are geared up for
a major surge in demand from medical device OEMs in the coming months.'
21 February, 2000
For further information please contact:
| David Baines, Director - Medical Applications at City Technology on | + 44 (0)23 9232 5511 | or email david.baines@citytech.co.uk |
| Sally Davis at The PR Department on | + 44 23 9266 1600. | or email sally@theprdepartment.co.uk |